Patients with lymphoma may need transfusions for different reasons during the course of their care. For instance, CAR-T therapy and their associated treatments, such as the chemotherapy prior to CAR-T infusion, may induce acute and delayed cytopenias (a drop in the number of cells in the blood) in some people, who may then require one or more transfusions.

A project has been initiated and implemented by LYSA, the University Hospital of Rennes and Rennes local EFS to analyse the impact of transfusion needs of patients treated with CAR T-cells in terms of toxicities, quality of life, and possible impacts on treatment efficacy.

This project will use pseudonymized data (i.e., it is not possible to identify the patients with this data) from the patient medical records that are available in the DESCAR-T registry or will be retrieved via local EFS transfusion databases. Analyses will begin in January 2023 and will be performed by the LYSARC.

To the patients in the DESCAR-T registry, diagnosed with lymphoma, if you wish to object to the use of your data for this analysis, you can contact the doctor at your care centre for your treatment by CAR T-cells or make a request at dpo@lysarc.org. You can find more details on your rights regarding your data in the section “I am participating or have participated in a clinical trial“.